Keyword: U.S. Federal Trade Commission
Roche has said a delay in the U.S. regulatory review of its takeover of Spark Therapeutics is “not unusual.” But a third delay is anything but normal.
The Spark shares Roche had tendered has actually dropped, from 29.4% early this month, to 26.1%.
Many years into an investigation over a "pay-for-delay" payment on Opana ER, the FTC says Impax violated competition law.
Turns out shareholders aren’t the only ones who have some issues with Bristol-Myers Squibb’s proposed $74 billion Celgene merger.
Novo Nordisk has at least four more years to build up its newer diabetes drugs before they face Teva's versions of its $2.67B blockbuster Victoza.
Years after Teva entered an FTC settlement on "pay-for-delay" deals, the parties on Tuesday expanded the agreement.
Trial lawyer "bad drug" TV ads need better regulation, a new coalition of national patient and physician advocacy groups says.
After an FTC crackdown against AbbVie, pharmacy chains claim they overpaid for AndroGel because "sham" patent suits delayed cheap generics.
A U.S. judge ordered AbbVie and a partner to pay $448 million for illegally blocking AndroGel competition with "sham" patent lawsuits.
The generics sector has been looking to M&A as a way to combat pricing pressure. But that strategy just got a whole lot less attractive.